Clinical trial

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

NCT00063310

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Leuprolide acetate Normalized identity: leuprolide acetateView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-03-01

PhasePHASE2

Conditions

Alzheimer Diseaseverified · MONDO: Alzheimer disease

Interventions

Leuprolide acetateDRUG · verified · RxNorm: leuprolide acetate

Sponsors & collaborators

Voyager Pharmaceutical Corporationlead sponsor

Mapped research locations

Fort LauderdaleFlorida, United States1 St. PetersburgFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00063310 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.